15 November 2019 - Deborah Wilkes
Abbott, Unilever, the US Consumer Healthcare Products Association (CHPA) and Teva Pharmaceutical have all announced people changes.
Abbott names new chief executive
Abbott said Miles White would step down as chief executive officer on 31 March 2020 after 21 years in the post. He will remain executive chairman.
White will be replaced by Robert Ford, a 23-year Abbott veteran who is currently president and chief operating officer.
New chair for Unilever
Unilever has announced that Marijn Dekkers has stepped down as chairman with immediate effect but will remain a non-executive director.
The Anglo-Dutch company said Dekkers wanted to focus on his growing responsibilities as founder and chairman of Novalis LifeSciences, an investment and advisory firm.
Dekkers had been Unilever’s chairman since 2016. He was previously chairman of Bayer's management board.
Nils Andersen – a non-executive director of Unilever – is replacing Dekkers. Andersen is a former group chief executive officer of Maersk and a former president and chief executive officer of Carlsberg and Carlsberg Breweries.
New chair of CHPA Educational Foundation
The US CHPA has made Amardeep Kahlon – chief marketing officer and vice president of US marketing at GlaxoSmithKline Consumer Healthcare – the new chair of the CHPA Educational Foundation’s board of directors.
Kahlon succeeds Christopher DeWolf – president and chief executive officer of Lil’ Drug Store Products – who was the foundation’s interim chair.
The CHPA Educational Foundation’s mission is to be the “trusted source of information on the responsible use of consumer healthcare products including OTC medicines and dietary supplements”. It is a non-profit organisation.
Teva names new finance chief
Teva Pharmaceutical has appointed Eli Kalif as executive vice president and chief financial officer with effect from 22 December 2019.
Kalif joins the Israeli generics giant from technology company Flex where he was senior vice president finance for global operations, components and services.
He replaces Michael McClellan who Teva announced in August 2019 was stepping down for "personal reasons" (click here to read the News story).